Monday, November 25, 2024
HomeTagsNMTi-ADCs

NMTi-ADCs

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

Myricx Bio, a UK biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), announced...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics